EnsiliTech, a biotech startup based in Bristol, has successfully raised £4.5 million in seed funding, marking a notable milestone in its mission to change the pharmaceutical industry’s approach to storing and transporting medications. The current reliance on a “cold chain” system, which involves refrigeration and freezing, is both costly and energy-intensive, leading to significant losses due to breakdowns. With EnsiliTech’s new funding, their Ensilication technology aims to offer a solution by stabilizing therapeutics at room temperature, thus simplifying global logistics and reducing environmental impact.
The traditional “cold chain” storage and transportation system has been a critical component in the biopharmaceutical industry for over five decades. However, its inefficiencies have cost the industry up to £26 billion each year. Many efforts have been made to mitigate these issues, but EnsiliTech’s recent developments aim to address them by eliminating the need for constant refrigeration, especially in regions lacking reliable infrastructure. Ensilication is poised to revolutionize how medicines are handled globally by allowing them to withstand higher temperatures without degradation.
What is Ensilication?
Ensilication, a patented technology developed by EnsiliTech, involves using inorganic silica material to form a protective coat around biological substances. This innovative method keeps pharmaceuticals stable and effective, regardless of external temperature or humidity changes. With no need for cold-chain logistics, life-saving treatments can be more easily distributed worldwide.
How Will This Investment Impact Global Healthcare?
This £4.5 million investment, led by Eos Advisory and supported by Calculus Capital and others, allows EnsiliTech to accelerate the integration of Ensilication into various biopharmaceutical applications. EnsiliTech will expand its capabilities with new hires and upgraded infrastructures, ensuring broader access to its technology. Key partners such as Eos Advisory and Calculus Capital have expressed optimism about EnsiliTech’s future. Anne Muir of Eos Advisory mentioned,
“EnsiliTech has the technology to transform how vaccines and other therapeutics are transported and stored.”
Elizabeth Klein-Edmonds from Calculus Capital remarked on the commercial momentum EnsiliTech is experiencing. The company’s unique platform could reshape the pharmaceutical landscape, offering potential applications that significantly enhance patient care across global health systems.
CEO Dr. Asel Sartbaeva outlined the vision, noting that the reduced need for refrigeration could significantly impact both supply chain costs and environmental footprints, while also improving health outcomes. She stated,
“Our mission is to ensure that life-saving medicines and vaccines reach everyone, everywhere, regardless of infrastructure or geography.”
EnsiliTech boasts a predominantly female leadership team, attracting investment from groups such as HERmesa, dedicated to supporting female-led businesses. This commitment reflects the company’s forward-thinking approach towards diversity and scientific excellence.
The strategic use of Ensilication could lead to breakthrough changes in the therapeutic market, paving the way for the introduction of mRNA therapies, vaccines, and antibodies to new global markets. With EnsiliTech’s approach, the startup could emerge as a leader in biologics thermostabilisation, which signifies a move towards more sustainable and accessible healthcare solutions.
